GammaCan to Present and Webcast at Acumen BioFin Rodman & Renshaw 4th Annual Global Healthcare Conference
14 May 2007 - 6:23PM
Business Wire
GammaCan International, Inc. ("GammaCan" or "the Company")
(OTCBB:GCAN), a developer of immunotherapies for the treatment of
cancer, today announced that Patrick Schnegelsberg, Chief Executive
Officer, is scheduled to present VitiGam�, GammaCan's lead product
under development for the treatment of Stage III and Stage IV
melanoma at the Acumen BioFin Rodman & Renshaw 4th Annual
Global Healthcare Conference. GammaCan�s presentation is scheduled
for Monday, May 14th at 2:55 PM CST (8:55 AM EDT). Interested
parties may access a live audio webcast of the presentation via the
investor information section of the GammaCan website,
www.GammaCan.com. A replay of the presentation will be archived on
the site for 30 days following the presentation. About GammaCan
GammaCan develops innovative immunotherapy and related approaches
to treat cancer. GammaCan's platform technology is based on IgGs, a
safe, relatively non-toxic human plasma-based product used to treat
a variety of immune deficiencies and autoimmune diseases. In
cancer, IgG-based therapies work by strengthening the patient's
immune system. Many experts currently view immunotherapy as a
future alternative to chemotherapy. For more information about
GammaCan, visit www.GammaCan.com. About VitiGam� VitiGam� is a
first-in-class IgG-based anti-cancer immunotherapy being developed
for the treatment of Stage III and Stage IV melanoma. GammaCan is
planning to submit its Investigational New Drug Application (IND)
for VitiGam� to the FDA in the near future. The Company is
expecting to commence human clinical trials shortly thereafter.
VitiGam� is an IgG-based product manufactured from the plasma of
donors with Vitiligo, a benign skin condition affecting up to 2% of
the general population. Studies have shown that this "enriched" IgG
formulation contains potent anti-melanoma activity. Based on these
studies, GammaCan expects VitiGam� to provide both, specific
anti-melanoma activity (directed against melanoma cells), and
non-specific anti-cancer activity. About Metastatic Melanoma
Melanoma is a deadly form of skin cancer. According to the American
Cancer Society, melanoma accounts for approximately 4% of all skin
cancers but causes about 75% of all skin cancer-related deaths. An
estimated 60,000 people will be diagnosed and nearly 8,000 people
will die from melanoma in 2007 in the U.S. alone. If rapidly
diagnosed and surgically removed, early-stage melanoma is usually
curable. However, for patients with metastatic melanoma, the
prognosis is poor resulting from limited treatment alternatives,
and a median survival time of 8.5 months and a 5-year survival rate
of 3%. There has been little change in these results in excess of
25 years. The incidence of melanoma has increased more rapidly than
any other cancer during the past 10 years. The last drug to treat
patients with melanoma was approved by the FDA 30 years ago. Safe
Harbor Statement Statements in this document that are not purely
historical are forward-looking statements. Forward-looking
statements in this release include statements regarding: the
commercialization of anti-cancer immunotherapies and the Company's
efforts to develop therapies to boost the immune systems of cancer
patients by the use of IgG-based therapy. Actual outcomes and the
Company's actual results could differ materially from those in such
forward-looking statements. Factors that could cause actual results
to differ materially include risks and uncertainties such as the
inability to finance the planned development of the technology, the
inability to hire appropriate staff to develop the technology,
unforeseen technical difficulties in developing the technology, the
inability to obtain regulatory approval for human use, competitors'
therapies proving to be more effective, cheaper or otherwise
preferable for consumers, the inability to market the product we
produce, all of which could, among other things, delay or prevent
product release, as well as other factors expressed from time to
time in GammaCan's periodic filings with the Securities and
Exchange Commission (the "SEC"). As a result, this press release
should be read in conjunction with GammaCan's periodic filings with
the SEC, which are incorporated herein by reference. The
forward-looking statements contained herein are made only as of the
date of this press release, and GammaCan undertakes no obligation
to publicly update such forward-looking statements to reflect
subsequent events or circumstances.
Greater Cannabis (PK) (USOTC:GCAN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Greater Cannabis (PK) (USOTC:GCAN)
Historical Stock Chart
From Jul 2023 to Jul 2024